Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…
Dow Climbs More Than 400 Points, S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday.
Analyzing Immunocore Hldgs’s Short Interest
Immunocore Hldgs's (NASDAQ:IMCR) short percent of float has fallen 15.71% since its last report. The company recently reported that it has 902 thousand shares sold short, which is 2.36% of all regular shares that are available for trading.
Immunocore Shares Fall After Early Solid Cancer Trial Data Of TCR Therapy
Immunocore Holdings plc (NASDAQ:IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well…
Enphase Energy, Immunocore And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Friday. Here are some big stocks recording gains in today’s session.
US Stocks Open Higher, Dow Surges 300 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
Ladenburg Thalmann Initiates Coverage On Immunocore Hldgs with Buy Rating, Announces Price Target of $82
Ladenburg Thalmann analyst Ahu Demir initiates coverage on Immunocore Hldgs (NASDAQ:IMCR) with a Buy rating and announces Price Target of $82.